Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Krakow on Genetic Testing in Ovarian Cancer

May 30th 2018

Deborah Krakow, MD, professor and chair, Department of Obstetrics and Gynecology, professor of Orthopaedic Surgery and Human Genetics, University of California, Los Angeles, discusses genetic testing in patients with ovarian cancer.

Dr. McCann on Combination Trials With PARP Inhibitors in Ovarian Cancer

May 30th 2018

Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses combination clinical trials of PARP inhibitors in patients with ovarian cancer.

Dr. Memarzadeh on p53 Reactivation in Ovarian Cancer

May 29th 2018

Sanaz Memarzadeh, MD, PhD, gynecologic oncologist, professor of obstetrics and gynecology, University of California, Los Angeles, discusses p53 reactivation in the treatment of patients with ovarian cancer.

Dr. Konecny on the Use of PARP Inhibitors in Patients With Ovarian Cancer

May 29th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Essel Discusses Adverse Events of Bevacizumab in Ovarian Cancer

May 25th 2018

Kathleen Essel, MD, fellow, University of Oklahoma Health Science Center, discusses adverse events with bevacizumab (Avastin) in ovarian cancer.

Dr. Slamon on PARP Inhibitors in Ovarian Cancer

May 25th 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Cohen on the Evolution of Surgery in Ovarian Cancer

May 25th 2018

Joshua G. Cohen, MD, assistant professor, Division of Gynecologic Oncology, University of California, Los Angeles, discusses the evolution of surgery in the treatment of patients with ovarian cancer.

Dr. Monk on the FORWARD I Trial in Ovarian Cancer

May 24th 2018

Bradley J. Monk, MD, FACOG, FACS, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Arizona Oncology, discusses the FORWARD I trial in ovarian cancer.

Dr. Wingo Discusses Neoadjuvant Chemotherapy in Ovarian Cancer

May 17th 2018

Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses the use of neoadjuvant chemotherapy in the treatment of patients with ovarian cancer.

Wingo Weighs in on Surgical Approaches in Ovarian Cancer

May 15th 2018

Shana Wingo, MD, discusses the surgical landscape in patients with newly diagnosed ovarian cancer.

Treatment Approaches Evolving in Recurrent Ovarian Cancer

May 14th 2018

Dennis R. Scribner Jr, MD, discusses the elements and evolution of treatment for patients with recurrent ovarian cancer.

Genetic Testing Becoming More Widespread in Ovarian Cancer, But Challenges Remain

May 12th 2018

Mike Janicek, MD, discusses the importance of genetic testing and how the ovarian field can benefit from a better understanding of it through genetic counselors and self-education.

Expert Shares Intriguing Ovarian Cancer Cases, Highlights Individualized Treatment

May 11th 2018

Matthew Borst, MD, highlights the need for neoadjuvant therapy versus upfront surgery in newly diagnosed patients, effective treatment management for recurrent platinum-sensitive disease, and what to do in the third-line setting and beyond.

Frontline Treatment in Ovarian Cancer Could Undergo Transformation

May 10th 2018

Heather Dalton, MD, discusses the developing standard of care for the frontline treatment of patients with ovarian cancer.

Dr. Essel Discusses Long-Term Bevacizumab in Ovarian Cancer

May 9th 2018

Kathleen Essel, MD, fellow, University of Oklahoma Health Science Center, discusses a study on the effects of long-term bevacizumab (Avastin) use in patients with ovarian cancer.

Expert Encourages Widespread Use of ERAS in Ovarian Cancer

May 9th 2018

Snehal Bhoola, MD, discusses the implementation of enhanced recovery after surgery in ovarian cancer.

Olaparib Tablets Approved in Europe for Ovarian Cancer, Regardless of BRCA Status

May 9th 2018

The European Commission has approved olaparib tablets (Lynparza) as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube or primary peritoneal cancer.

Rucaparib FDA Approval Creates Trifecta of Maintenance PARP Inhibitors in Ovarian Cancer

May 8th 2018

Lyndsay Willmott, MD, discusses the use of PARP inhibitors in patients with ovarian cancer and details the mechanisms of resistance that have been identified so far.

Monk Highlights Clinical Trials in Recurrent Ovarian Cancer

May 7th 2018

Bradley J. Monk, MD, FACOG, FACS, discusses the promise of new therapies and regimens in patients with ovarian cancer in the recurrent setting.

Dr. Borst on Homologous Recombination Deficiency in Patients With Ovarian Cancer

May 5th 2018

Matthew Borst, MD, director, GYN/Oncology, Banner Good Samaritan Regional Medical Center, clinical assistant professor of medicine, University of Arizona, Arizona Oncology, discusses homologous recombination deficiency (HRD) in patients with ovarian cancer.